Cohance FY26 Growth: Niche Tech, CDMO, Chemicals

  Published 11 months ago

Cohance's niche tech sales rise, pharma CDMO grows, specialty chemicals and API+ see strong gains.

  • Niche modalities like ADCs, oligonucleotides boost revenue, targeting mid‑20s percent FY26 for future growth targets.
  • Pharma CDMO revenue up over 30% excluding de‑stocking, driven by strong commercial execution and innovation.
  • Specialty chemicals rise 28% on AgChem recovery; API+ climbs 19% with new launches driving profits.

You might like these

3M India FY25: Mixed Results & Dividend

India's Stock Markets Rally on RBI Support, Global Optimism

Rupee Lags Despite Dollar Decline

RBL Bank Eyes Margin Recovery Ahead

Stallion India Q2 FY26 Revenue Surge

Go Digit Q2 Profit Soars 52%

FICCI Slams US Tariffs on Indian Exports

News that matters the most ⚡